help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mariotti, S.
Right arrow Articles by Pinchera, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mariotti, S.
Right arrow Articles by Pinchera, A.

Journal of Clinical Endocrinology & Metabolism, Vol 56, 467-473, Copyright © 1983 by Endocrine Society


ARTICLES

A new solid phase immunoradiometric assay for antithyroid microsomal antibody

S Mariotti, A Russova, S Pisani and A Pinchera

A new sensitive, quantitative, and specific immunoradiometric assay (IRMA) for antithyroid microsomal (anti-M) antibody has been developed. Samples to be tested are incubated within wells of polyvinyl microtiter plates coated with solubilized thyroid microsomal antigen. After removal of unbound material, anti-M antibody is detected by adding purified [125I]antihuman immunoglobulin G (IgG) antibody. Using 1.0 microliter serum, anti-M antibody was found by IRMA in all of the patients with Hashimoto's thyroiditis or idiopathic myxedema (n = 19), in 86% of those with Graves' disease (n = 42), in 10.9% of subjects with other nonautoimmune thyroid disorders (n = 37), and in 8.4% of normal controls (n = 71). A good correlation was found with the results obtained in anti-M antibody tests by passive hemagglutination. Using larger volumes of serum (up to 100 microliters), anti-M antibody detectable by IRMA was found in some patients with Graves' disease and negative passive hemagglutination tests. Quantitative measurements of anti-M antibody by IRMA could be performed using a standard IgG preparation containing high levels of anti-M antibody. The minimal detectable amount ranged between 1-2 ng IgG, corresponding to a sensitivity 15-30 times greater than that of the competitive binding radioassay. We suggest that the present IRMA may be proposed as a general technique for the detection of different organ-specific autoantibodies.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society